Actelion Pharmaceuticals Ltd.’s newly approved drug for pulmonary arterial hypertension, Opsumit (macitentan), is differentiated enough for the company to drop promotion in the U.S. of its major product, Tracleer, and commit its resources to the new follow-on.
On a conference call with analysts Oct. 21, Chief Operating Officer Otto Schwarz said that the company’s U.S
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?